These divergent clinical and molecular phenotypes have led to the hypothesis that the clinical symptomatology associated with FXTAS is related to a neurotoxic effect of increased levels of FMR1 mRNA in the nervous system. The gene discussed is FMR1; the disease is fragile X-associated tremor/ataxia syndrome.